# reload+after+2024-01-20 03:47:24.514081
address1§45 Wiggins Avenue
city§Bedford
state§MA
zip§01730
country§United States
phone§781 430 8200
website§https://www.stoketherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
fullTimeEmployees§117
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Edward M. Kaye M.D., Ph.D.', 'age': 74, 'title': 'CEO & Director', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 931212, 'exercisedValue': 0, 'unexercisedValue': 8672182}, {'maxAge': 1, 'name': 'Dr. Adrian R. Krainer Ph.D.', 'age': 64, 'title': 'Co-Founder & Independent Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 44000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen J. Tulipano CPA, MBA', 'age': 64, 'title': 'Chief Financial Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 619092, 'exercisedValue': 0, 'unexercisedValue': 718970}, {'maxAge': 1, 'name': 'Dr. Barry S. Ticho FACC, M.D., Ph.D.', 'age': 62, 'title': 'Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 688826, 'exercisedValue': 0, 'unexercisedValue': 1335890}, {'maxAge': 1, 'name': 'Ms. Isabel  Aznarez Ph.D.', 'age': 50, 'title': 'Co-Founder & Group VP of Discovery Research', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Huw M. Nash Ph.D.', 'age': 56, 'title': 'COO & Chief Business Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 429665, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Rojas', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Allan J.D.', 'age': 33, 'title': 'Corporate Secretary & General Counsel', 'yearBorn': 1990, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dawn  Kalmar', 'age': 45, 'title': 'Chief Communications Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joan  Wood', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.519
priceToSalesTrailing12Months§25.403309
currency§USD
dateShortInterest§1702598400
forwardEps§-2.36
pegRatio§0.1
exchange§NMS
quoteType§EQUITY
shortName§Stoke Therapeutics, Inc.
longName§Stoke Therapeutics, Inc.
firstTradeDateEpochUtc§1560951000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3e46cbf2-2a6a-3d80-9b42-929de37f3aad
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§6.0
targetMeanPrice§19.33
targetMedianPrice§18.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§8.524
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
